Wedbush analyst David Nierengarten initiates coverage on Aktis Oncology (NASDAQ:AKTS) with a Outp

BMO Capital analyst David Lebowitz initiates coverage on Aktis Oncology (NASDAQ:AKTS) with a Outp

A pullback in the AI trade has created opportunities for bargain-hunting investors, according to ana

Bank of America screened its AI baskets for Buy-rated stocks down over 20% from highs. Micron carrie

Aktis Oncology (NASDAQ:AKTS) reported quarterly losses of $(0.44) per share which missed the analyst

BOSTON, Aug. 13, 2026 (GLOBE NEWSWIRE) -- Aktis Oncology, Inc. (NASDAQ:AKTS) (“Aktis” or the “Compan

JP Morgan analyst Jessica Fye maintains Aktis Oncology (NASDAQ:AKTS) with a Overweight and raises

US stocks were mixed, Nasdaq fell 1%. DigitalOcean shares rose after strong revenue growth and earni

Gainers Vicore Pharma Holding (NASDAQ:VCRE) stock rose 149.8% to $42.47 during Monday's after-m

Gainers Innovative Eyewear (NASDAQ:LUCY) stock moved upwards by 95.4% to $1.49 during Monday's

Top Wall Street analysts changed outlook on top names. For all changes, including upgrades/downgrade

Raymond James analyst Christopher Raymond initiates coverage on Aktis Oncology (NASDAQ:AKTS) with

U.S. stocks were mixed, with the Dow Jones gaining 100 points. Rezolve AI (RZLV) jumped 11.9%, and o

Aktis Oncology trades at a $1.1B market cap with $540M cash, pricing its pipeline and Eli Lilly coll

HC Wainwright & Co. analyst Robert Burns maintains Aktis Oncology (NASDAQ:AKTS) with a Buy an

BOSTON, May 27, 2026 (GLOBE NEWSWIRE) -- Aktis Oncology, Inc. (NASDAQ:AKTS) (the “Company”), a clini

Data to be presented across two posters at the 2026 American Society of Clinical Oncology (ASCO) Ann

BOSTON, May 21, 2026 (GLOBE NEWSWIRE) -- Aktis Oncology, Inc. (NASDAQ:AKTS) (Aktis or the Company),

This clinical-stage biotech develops targeted radiopharmaceutical therapies for cancer using a propr

Aktis Oncology (NASDAQ:AKTS) reported quarterly losses of $(0.38) per share which beat the analyst c

BOSTON, May 11, 2026 (GLOBE NEWSWIRE) -- Aktis Oncology, Inc. (NASDAQ:AKTS) (Aktis or the Company),

BOSTON, May 06, 2026 (GLOBE NEWSWIRE) -- Aktis Oncology, Inc. (NASDAQ:AKTS) (the “Company”), a clini

Aktis Oncology, Inc. (NASDAQ:AKTS) (Aktis or the Company), a clinical-stage oncology company focused

BOSTON, May 04, 2026 (GLOBE NEWSWIRE) -- Aktis Oncology, Inc. (NASDAQ:AKTS) (Aktis or the Company),

Top analysts change outlook on Hyperfine Inc, Legence, and Aktis Oncology with Buy/Outperform rating

William Blair analyst Alexandra Ramsey initiates coverage on Aktis Oncology (NASDAQ:AKTS) with a

Aktis Oncology is initiated with a "Buy" rating, driven by its innovative miniprotein radioconjugate

Aktis Oncology, Inc. (NASDAQ:AKTS) (the "Company"), a clinical-stage oncology company focuse

The mean of analysts' price targets for Aktis (AKTS) points to a 74.7% upside in the stock. While th

BOSTON, April 16, 2026 (GLOBE NEWSWIRE) -- Aktis Oncology, Inc. (NASDAQ:AKTS) (the “Company”), a cli

HC Wainwright & Co. analyst Robert Burns maintains Aktis Oncology (NASDAQ:AKTS) with a Buy an

BOSTON, March 30, 2026 (GLOBE NEWSWIRE) -- Aktis Oncology, Inc. (NASDAQ:AKTS) (the “Company”), a cli

Top analysts change outlook on top names. See all analyst rating changes on Benzinga's analyst r

HC Wainwright & Co. analyst Robert Burns initiates coverage on Aktis Oncology (NASDAQ:AKTS) w

BOSTON, Feb. 24, 2026 (GLOBE NEWSWIRE) -- Aktis Oncology, Inc. (NASDAQ:AKTS), a clinical-stage oncol

U.S. FDA Fast Track designation granted to AKY-11891 for the treatment of adult patients with locall

BOSTON, Feb. 24, 2026 (GLOBE NEWSWIRE) -- Aktis Oncology, Inc. (NASDAQ:AKTS), a clinical-stage oncol

In the past week, a beneficial owner has continued to build a stake in insurance giant W.R.

Guru Stock PicksAndreas Halvorsen has made the following transactions:Add in RRX by 5.71%Stock News